Canaccord Genuity Maintains Buy on Staar Surgical, Raises Price Target to $32

Benzinga Newsdesk www.benzinga.com Positive 83.5%

Neg 0% Neu 0% Pos 83.5%

Canaccord Genuity analyst John Young maintains Staar Surgical (NASDAQ:STAA) with a Buy and raises the price target from $27 to $32.